# Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition

> **NCT00968097** · PHASE1 · TERMINATED · sponsor: **Institute for Neurodegenerative Disorders** · enrollment: 12 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** 123-I MNI-340

## Key facts

- **NCT ID:** NCT00968097
- **Lead sponsor:** Institute for Neurodegenerative Disorders
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Early Phase I study of \[123I\]MNI-340 did not evidence as marker of disease
- **Last updated:** 2019-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00968097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00968097, "Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00968097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*